Physician profile
Roger Oen
NPI 1710060165
$4,842.67
in general payments reported to CMS, 2019-2025
33 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $139 · 2021: $1,151 · 2022: $531 · 2023: $333 · 2024: $426 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $750.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.81 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $548.51 | 2019-2025 | Mounjaro, Kisunla, Trulicity |
| Pfizer INC. | $422.04 | 2019-2025 | |
| Eisai INC. | $376.72 | 2023-2025 | |
| Abbvie INC. | $348.03 | 2021-2025 | |
| Novo Nordisk INC | $248.06 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $207.32 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $202.29 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $166.65 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $160.92 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $144.83 | 2019 | |
| Paratek Pharmaceuticals, INC. | $125.00 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $112.81 | 2019 | |
| Allergan, INC. | $61.39 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $51.20 | 2022 | |
| Radius Health, INC. | $31.12 | 2019 | |
| Almatica Pharma LLC | $29.96 | 2025 | Teriparatide, Loreev Xr |
| Astellas Pharma US INC | $27.22 | 2024 | Veozah |
| Boston Scientific Corporation | $26.99 | 2019-2021 | |
| Gilead Sciences, INC. | $24.39 | 2024 | |
| Organon LLC | $23.59 | 2025 | Nexplanon |
| Janssen Pharmaceuticals, INC | $23.12 | 2021 | |
| Amgen INC. | $22.37 | 2019 | |
| Phadia US INC. | $22.29 | 2024 | Immunocap |
| Teleflex LLC | $21.14 | 2025 | Urolift |
| Inari Medical, INC. | $18.94 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Otsuka America Pharmaceutical, INC. | $18.53 | 2019 | |
| Baxter Healthcare | $18.37 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Teva Pharmaceuticals USA, INC. | $17.77 | 2019 | |
| Medela LLC | $16.51 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.92 | 2023 | Quviviq |
| Vertiflex, INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Oen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.